LEIDOS BIOMEDICAL RESEARCH, INC.
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH is a funding opportunity from LEIDOS BIOMEDICAL RESEARCH, INC., up to 5946332, closing July 31, 2028.
Jul 31, 2028
(731d left)Overview
This funding supports INSIGHT Protocol Number: 013, Inpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC). It is an international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for…